Immunostimulatory Defective Viral Genomes from Respiratory Syncytial Virus Promote a Strong Innate Antiviral Response during Infection in Mice and Humans

English version České info

Respiratory syncytial virus is a major cause of chronic lung damage, asthma exacerbations, and hospitalizations of infants, elders, and high-risk adults. Currently, there is no effective vaccine or treatment available to protect the general population from RSV infection. Here, we demonstrate that defective forms of RSV genomes naturally generated during infection effectively stimulate the antiviral response in vitro and in vivo. In human cells, RSV iDVGs trigger the antiviral response through a mechanism characterized by the potent activation of the transcription factor IRF1 and a dominant expression of the type III IFN gene IFNL1 (IFN-λ1). This study establishes for the first time that naturally occurring iDVGs trigger robust host antiviral responses to RSV in mice and humans and reveals new opportunities to potentiate the host response to RSV infection and minimize viral-induced pathology.

Vyšlo v časopise: Immunostimulatory Defective Viral Genomes from Respiratory Syncytial Virus Promote a Strong Innate Antiviral Response during Infection in Mice and Humans. PLoS Pathog 11(9): e32767. doi:10.1371/journal.ppat.1005122
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1005122

Souhrn

Zdroje

1. Dixit E, Kagan JC. (2013) Intracellular pathogen detection by RIG-I-like receptors. Advances in immunology 117: 99–125. doi: 10.1016/B978-0-12-410524-9.00004-9 23611287

2. Loo YM, Gale M Jr. (2011) Immune signaling by RIG-I-like receptors. Immunity 34(5): 680–92. doi: 10.1016/j.immuni.2011.05.003 21616437

3. Goubau D, Deddouche S, Reis ESC. (2013) Cytosolic sensing of viruses. Immunity 38(5): 855–69. doi: 10.1016/j.immuni.2013.05.007 23706667

4. Goswami R, Majumdar T, Dhar J, Chattopadhyay S, Bandyopadhyay SK, Verbovetskaya V, et al. (2013) Viral degradasome hijacks mitochondria to suppress innate immunity. Cell Res 23(8): 1025–42. doi: 10.1038/cr.2013.98 23877405

5. Guo Z, Chen LM, Zeng H, Gomez JA, Plowden J, Fujita T, et al. (2007) NS1 protein of influenza A virus inhibits the function of intracytoplasmic pathogen sensor, RIG-I. Am J Respir Cell Mol Biol 36(3): 263–9. 17053203

6. Versteeg GA, Garcia-Sastre A. (2010) Viral tricks to grid-lock the type I interferon system. Curr Opin Microbiol 13(4): 508–16. doi: 10.1016/j.mib.2010.05.009 20538505

7. Von Magnus P. (1954) Incomplete forms of influenza virus. Adv Virus Res 2: 59–79. 13228257

8. Calain P, Curran J, Kolakofsky D, Roux L. (1992) Molecular cloning of natural paramyxovirus copy-back defective interfering RNAs and their expression from DNA. Virology 191(1): 62–71. 1329337

9. Valdovinos MR, Gomez B. (2003) Establishment of respiratory syncytial virus persistence in cell lines: association with defective interfering particles. Intervirology 46(3): 190–8. 12867758

10. Shingai M, Ebihara T, Begum NA, Kato A, Honma T, Matsumoto K, et al. (2007) Differential type I IFN-inducing abilities of wild-type versus vaccine strains of measles virus. J Immunol 179(9): 6123–33. 17947687

11. Lazzarini RA, Keene JD, Schubert M. (1981) The origins of defective interfering particles of the negative-strand RNA viruses. Cell 26(2 Pt 2): 145–54. 7037195

12. Strahle L, Garcin D, Kolakofsky D. (2006) Sendai virus defective-interfering genomes and the activation of interferon-beta. Virology 351(1): 101–11. 16631220

13. Pathak KB, Nagy PD. (2009) Defective Interfering RNAs: Foes of Viruses and Friends of Virologists. Viruses 1(3): 895–919. doi: 10.3390/v1030895 21994575

14. Yount JS, Kraus TA, Horvath CM, Moran TM, Lopez CB. (2006) A novel role for viral-defective interfering particles in enhancing dendritic cell maturation. J Immunol 177(7): 4503–13. 16982887

15. Mercado-Lopez X, Cotter CR, Kim WK, Sun Y, Munoz L, Tapia K, et al. (2013) Highly immunostimulatory RNA derived from a Sendai virus defective viral genome. Vaccine 31(48): 5713–21. doi: 10.1016/j.vaccine.2013.09.040 24099876

16. Dimmock NJ, Marriott AC. (2006) In vivo antiviral activity: defective interfering virus protects better against virulent Influenza A virus than avirulent virus. J Gen Virol 87(Pt 5): 1259–65. 16603528

17. Tapia K, Kim WK, Sun Y, Mercado-Lopez X, Dunay E, Wise M, et al. (2013) Defective viral genomes arising in vivo provide critical danger signals for the triggering of lung antiviral immunity. PLoS Pathog 9(10): e1003703. doi: 10.1371/journal.ppat.1003703 24204261

18. Baum A, Sachidanandam R, Garcia-Sastre A. (2010) Preference of RIG-I for short viral RNA molecules in infected cells revealed by next-generation sequencing. Proc Natl Acad Sci U S A 107(37): 16303–8. doi: 10.1073/pnas.1005077107 20805493

19. Yount JS, Gitlin L, Moran TM, Lopez CB. (2008) MDA5 Participates in the Detection of Paramyxovirus Infection and Is Essential for the Early Activation of Dendritic Cells in Response to Sendai Virus Defective Interfering Particles. J Immunol 180(7): 4910–8. 18354215

20. Saira K, Lin X, DePasse JV, Halpin R, Twaddle A, Stockwell T, et al. (2013) Sequence analysis of in vivo defective interfering-like RNA of influenza A H1N1 pandemic virus. J Virol 87(14): 8064–74. doi: 10.1128/JVI.00240-13 23678180

21. Johnston MD. (1981) The characteristics required for a Sendai virus preparation to induce high levels of interferon in human lymphoblastoid cells. J Gen Virol 56(Pt 1): 175–84. 6170730

22. Inoue M, Hoxie JA, Reddy MV, Srinivasan A, Reddy EP. (1991) Mechanisms associated with the generation of biologically active human immunodeficiency virus type 1 particles from defective proviruses. Proceedings of the National Academy of Sciences of the United States of America 88(6): 2278–82. 2006168

23. Li D, Lott WB, Lowry K, Jones A, Thu HM, Aaskov J. (2011) Defective interfering viral particles in acute dengue infections. PLoS One 6(4): e19447. doi: 10.1371/journal.pone.0019447 21559384

24. Hervas D, Reina J, Yanez A, del Valle JM, Figuerola J, Hervas JA. (2012) Epidemiology of hospitalization for acute bronchiolitis in children: differences between RSV and non-RSV bronchiolitis. Eur J Clin Microbiol Infect Dis 31(8): 1975–81. doi: 10.1007/s10096-011-1529-y 22240853

25. Miller EK, Gebretsadik T, Carroll KN, Dupont WD, Mohamed YA, Morin LL, et al. (2013) Viral etiologies of infant bronchiolitis, croup and upper respiratory illness during 4 consecutive years. Pediatr Infect Dis J 32(9): 950–5. doi: 10.1097/INF.0b013e31829b7e43 23694832

26. Lee N, Lui GC, Wong KT, Li TC, Tse EC, Chan JY, et al. (2013) High morbidity and mortality in adults hospitalized for respiratory syncytial virus infections. Clin Infect Dis 57(8): 1069–77. doi: 10.1093/cid/cit471 23876395

27. Lotz MT, Moore ML, Peebles RS Jr. (2013) Respiratory syncytial virus and reactive airway disease. Curr Top Microbiol Immunol 372: 105–18. doi: 10.1007/978-3-642-38919-1_5 24362686

28. Krishnamoorthy N, Khare A, Oriss TB, Raundhal M, Morse C, Yarlagadda M, et al. (2012) Early infection with respiratory syncytial virus impairs regulatory T cell function and increases susceptibility to allergic asthma. Nat Med 18(10): 1525–30. doi: 10.1038/nm.2896 22961107

29. Zomer-Kooijker K, van der Ent CK, Ermers MJ, Uiterwaal CS, Rovers MM, Bont LJ. (2014) Increased risk of wheeze and decreased lung function after respiratory syncytial virus infection. PLoS One 9(1): e87162. doi: 10.1371/journal.pone.0087162 24498037

30. Barik S. (2013) Respiratory syncytial virus mechanisms to interfere with type 1 interferons. Curr Top Microbiol Immunol 372: 173–91. doi: 10.1007/978-3-642-38919-1_9 24362690

31. Ling Z, Tran KC, Teng MN. (2009) Human respiratory syncytial virus nonstructural protein NS2 antagonizes the activation of beta interferon transcription by interacting with RIG-I. J Virol 83(8): 3734–42. doi: 10.1128/JVI.02434-08 19193793

32. Moore EC, Barber J, Tripp RA. (2008) Respiratory syncytial virus (RSV) attachment and nonstructural proteins modify the type I interferon response associated with suppressor of cytokine signaling (SOCS) proteins and IFN-stimulated gene-15 (ISG15). Virol J 5: 116. doi: 10.1186/1743-422X-5-116 18851747

33. Ostler T, Davidson W, Ehl S. (2002) Virus clearance and immunopathology by CD8(+) T cells during infection with respiratory syncytial virus are mediated by IFN-gamma. Eur J Immunol 32(8): 2117–23. 12209623

34. Bruder D, Srikiatkhachorn A, Enelow RI. (2006) Cellular immunity and lung injury in respiratory virus infection. Viral Immunol 19(2): 147–55. 16817757

35. Smit JJ, Rudd BD, Lukacs NW. (2006) Plasmacytoid dendritic cells inhibit pulmonary immunopathology and promote clearance of respiratory syncytial virus. J Exp Med 203(5): 1153–9. 16682497

36. Phipps S, Lam CE, Mahalingam S, Newhouse M, Ramirez R, Rosenberg HF, et al. (2007) Eosinophils contribute to innate antiviral immunity and promote clearance of respiratory syncytial virus. Blood 110(5): 1578–86. 17495130

37. Cave DR, Hendrickson FM, Huang AS. (1985) Defective interfering virus particles modulate virulence. Journal of virology 55(2): 366–73. 2991562

38. Lopez CB. (2014) Defective viral genomes: critical danger signals of viral infections. Journal of virology 88(16): 8720–3. doi: 10.1128/JVI.00707-14 24872580

39. Donnelly RP, Kotenko SV. (2010) Interferon-lambda: a new addition to an old family. Journal of interferon & cytokine research: the official journal of the International Society for Interferon and Cytokine Research 30(8): 555–64.

40. Ding S, Robek MD. (2014) Peroxisomal MAVS activates IRF1-mediated IFN-lambda production. Nature immunology 15(8): 700–1. doi: 10.1038/ni.2924 25045870

41. Dixit E, Boulant S, Zhang Y, Lee AS, Odendall C, Shum B, et al. (2010) Peroxisomes are signaling platforms for antiviral innate immunity. Cell 141(4): 668–81. doi: 10.1016/j.cell.2010.04.018 20451243

42. Odendall C, Dixit E, Stavru F, Bierne H, Franz KM, Durbin AF, et al. (2014) Diverse intracellular pathogens activate type III interferon expression from peroxisomes. Nature immunology 15(8): 717–26. doi: 10.1038/ni.2915 24952503

43. Davis IC, Sullender WM, Hickman-Davis JM, Lindsey JR, Matalon S. (2004) Nucleotide-mediated inhibition of alveolar fluid clearance in BALB/c mice after respiratory syncytial virus infection. American journal of physiology Lung cellular and molecular physiology 286(1): L112–20. 12948936

44. Castro SM, Guerrero-Plata A, Suarez-Real G, Adegboyega PA, Colasurdo GN, Khan AM, et al. (2006) Antioxidant treatment ameliorates respiratory syncytial virus-induced disease and lung inflammation. Am J Resp Crit Care 174(12): 1361–9.

45. Stokes KL, Chi MH, Sakamoto K, Newcomb DC, Currier MG, Huckabee MM, et al. (2011) Differential pathogenesis of respiratory syncytial virus clinical isolates in BALB/c mice. J Virol 85(12): 5782–93. doi: 10.1128/JVI.01693-10 21471228

46. Quan FS, Kim Y, Lee S, Yi H, Kang SM, Bozja J, et al. (2011) Viruslike particle vaccine induces protection against respiratory syncytial virus infection in mice. J Infect Dis 204(7): 987–95. doi: 10.1093/infdis/jir474 21881112

47. Bolger G, Lapeyre N, Dansereau N, Lagace L, Berry G, Klosowski K, et al. (2005) Primary infection of mice with high titer inoculum respiratory syncytial virus: characterization and response to antiviral therapy. Canadian journal of physiology and pharmacology 83(2): 198–213. 15791294

48. Crotta S, Davidson S, Mahlakoiv T, Desmet CJ, Buckwalter MR, Albert ML, et al. (2013) Type I and type III interferons drive redundant amplification loops to induce a transcriptional signature in influenza-infected airway epithelia. PLoS Pathog 9(11): e1003773. doi: 10.1371/journal.ppat.1003773 24278020

49. Kotenko SV. (2011) IFN-lambdas. Current opinion in immunology 23(5): 583–90. doi: 10.1016/j.coi.2011.07.007 21840693

50. Jewell NA, Cline T, Mertz SE, Smirnov SV, Flano E, Schindler C, et al. (2010) Lambda interferon is the predominant interferon induced by influenza A virus infection in vivo. Journal of virology 84(21): 11515–22. doi: 10.1128/JVI.01703-09 20739515

51. Pott J, Mahlakoiv T, Mordstein M, Duerr CU, Michiels T, Stockinger S, et al. (2011) IFN-lambda determines the intestinal epithelial antiviral host defense. Proceedings of the National Academy of Sciences of the United States of America 108(19): 7944–9. doi: 10.1073/pnas.1100552108 21518880

52. Collins PL, Melero JA. (2011) Progress in understanding and controlling respiratory syncytial virus: Still crazy after all these years. Virus Res 162(1–2): 80–99. doi: 10.1016/j.virusres.2011.09.020 21963675

53. Selvaggi C, Pierangeli A, Fabiani M, Spano L, Nicolai A, Papoff P, et al. (2014) Interferon lambda 1–3 expression in infants hospitalized for RSV or HRV associated bronchiolitis. The Journal of infection 68(5): 467–77. doi: 10.1016/j.jinf.2013.12.010 24389019

54. Zhang Z, Shi L, Song L, Ephrem E, Petri M, Sullivan KE. (2015) Interferon regulatory factor 1 marks activated genes and can induce target gene expression in systemic lupus erythematosus. Arthritis & rheumatology 67(3): 785–96.

55. Cooper PR, Panettieri RA Jr. (2008) Steroids completely reverse albuterol-induced beta(2)-adrenergic receptor tolerance in human small airways. J Allergy Clin Immunol 122(4): 734–40. doi: 10.1016/j.jaci.2008.07.040 18774166